Background: The long-acting antimalarial drug piperaquine can be metabolized into the carboxylic acid metabolite (PQM). However, the clinical relevance of PQM remains unclear.
Objectives: The pharmacodynamics/pharmacokinetics of PQM were studied.
Methods: The antimalarial activity of PQM was studied in vitro (Plasmodium strains Pf3D7 and PfDd2) and in vivo (murine Plasmodium yoelii). The toxicity of PQM was evaluated in mice, in terms of the general measures of animal well-being, serum biochemical examination and ECG monitoring. The pharmacokinetic profiles of piperaquine and its metabolite PQM were investigated in healthy subjects after recommended oral doses of piperaquine.
Results: PQM showed no relevant in vitro antimalarial activity (IC50 > 1.0 μM) with no significant toxicity. After recommended oral administration of piperaquine to healthy subjects, the maximum concentration of PQM was less than 30.0 nM, and it did not accumulate after repeated dosing.
Conclusions: With a low antimalarial potency, PQM should not contribute to the efficacy of piperaquine with clinically acceptable doses.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jac/dkad349 | DOI Listing |
BMC Psychol
November 2024
CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
Nat Commun
November 2024
State Key Laboratory of Conservation and Utilization of Bio-resources in Yunnan, Yunnan Key Laboratory of Cell Metabolism and Diseases, Center for Life Sciences, School of Life Sciences, Yunnan University, Kunming, China.
Vaccine
December 2024
Food and Drugs Authority, P. O. Box CT 2783 Accra, Ghana; PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, the Netherlands. Electronic address:
Introduction: The development of COVID-19 vaccines during the pandemic occurred with an unprecedented speed, requiring extraordinary post-approval safety monitoring to facilitate ongoing evaluation of their benefit-risk profile. In Ghana, the Food and Drugs Authority granted emergency use authorization to six of these vaccines including the two mRNA COVID-19 vaccines, namely, Pfizer-BioNTech and Moderna COVID-19 vaccines. The objective of the study was to estimate the incidence of adverse events following immunization (AEFIs) and adverse events of special interest (AESIs) in persons vaccinated with mRNA COVID-19 vaccines, and to identify factors associated with the development of AEFIs.
View Article and Find Full Text PDFOrg Lett
October 2024
Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. China.
Med Dosim
September 2024
Varian Medical Systems 3100 Hansen ID, USA.
To develop a Knowledge Based Planning (KBP) model for creating quantifiably high quality VMAT treatment plans in a single click for head and neck cases treated Simultaneous Integrated Boost (SIB) with bilateral parotid involvement (BPI) where both parotids are near, abutting or partially overlapping target volume. Eclipse RapidPlan and the publicly available PlanScorecard tool were used to assess existing Head and Neck RapidPlan models on two representative cases. The best performer was used as a foundation model to assist in creating new initial training set doses from previously treated cases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!